- Home
- SGN vs DRMA Comparison
SGN vs DRMA Comparison
Compare SGN & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- DRMA
- Stock Information
- Founded
- SGN 2019
- DRMA 2014
- Country
- SGN United States
- DRMA United States
- Employees
- SGN N/A
- DRMA N/A
- Industry
- SGN
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- DRMA Health Care
- Exchange
- SGN Nasdaq
- DRMA Nasdaq
- Market Cap
- SGN 3.8M
- DRMA 4.5M
- IPO Year
- SGN 2023
- DRMA 2021
- Fundamental
- Price
- SGN $1.08
- DRMA $0.60
- Analyst Decision
- SGN
- DRMA Strong Buy
- Analyst Count
- SGN 0
- DRMA 1
- Target Price
- SGN N/A
- DRMA $3.00
- AVG Volume (30 Days)
- SGN 1.3M
- DRMA 94.5K
- Earning Date
- SGN 08-18-2025
- DRMA 08-06-2025
- Dividend Yield
- SGN N/A
- DRMA N/A
- EPS Growth
- SGN N/A
- DRMA N/A
- EPS
- SGN N/A
- DRMA N/A
- Revenue
- SGN $529,282.00
- DRMA N/A
- Revenue This Year
- SGN N/A
- DRMA N/A
- Revenue Next Year
- SGN N/A
- DRMA N/A
- P/E Ratio
- SGN N/A
- DRMA N/A
- Revenue Growth
- SGN 8.42
- DRMA N/A
- 52 Week Low
- SGN $0.44
- DRMA $0.57
- 52 Week High
- SGN $36.70
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- SGN 52.82
- DRMA 29.24
- Support Level
- SGN $0.92
- DRMA $0.57
- Resistance Level
- SGN $1.35
- DRMA $0.63
- Average True Range (ATR)
- SGN 0.17
- DRMA 0.04
- MACD
- SGN -0.02
- DRMA -0.01
- Stochastic Oscillator
- SGN 46.94
- DRMA 11.55
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.